172 results
8-K
EX-99.1
HBIO
Harvard Bioscience Inc.
7 May 24
Harvard Bioscience Announces First Quarter 2024 Financial Results
7:00am
Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “expect,” “plan
8-K
EX-10.1
HBIO
Harvard Bioscience Inc.
3 Apr 24
Entry into a Material Definitive Agreement
8:01am
with respect to accounts receivable and inventory); plus
(xii) one-time non-recurring costs associated with the settlement of the Biostage Litigation; plus … OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER
8-K
EX-99.1
HBIO
Harvard Bioscience Inc.
7 Mar 24
Harvard Bioscience Announces Fourth Quarter 2023 Financial Results
7:00am
of intangibles related to acquisitions, litigation settlement, restructuring and other costs, unrealized gain/loss on equity securities, income taxes … forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward
8-K
EX-99.1
rg5rtyak
5 Jan 24
Results of Operations and Financial Condition
5:01pm
8-K
EX-99.1
e3qx0gfo
7 Nov 23
Harvard Bioscience Announces Third Quarter 2023 Financial Results
7:00am
8-K
EX-99.1
1cu d51zz3i4ypljzp
8 Aug 23
Harvard Bioscience Announces Second Quarter 2023 Financial Results
9:05am
8-K
EX-99.1
da6o l49jdt555
20 Jun 23
Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer
8:15am
8-K
EX-10.1
cxt95j3yx uh
20 Jun 23
Harvard Bioscience Appoints Jennifer Cote as Chief Financial Officer
8:15am
8-K
EX-99.1
o7hwkavg r3vf
25 Apr 23
Harvard Bioscience Announces First Quarter 2023 Financial Results
8:00am
8-K
EX-99.1
a47oy4k3if8g
12 Dec 22
Harvard Bioscience Announces CFO Transition
8:31am
8-K
EX-99.1
68d7vpx4k749o
8 Nov 22
Harvard Bioscience Announces Third Quarter 2022 Financial Results
4:02pm
8-K
EX-99.1
lt5ybrm
4 Aug 22
Harvard Bioscience Announces Second Quarter 2022 Financial Results
7:01am